Neovacs

About

Neovacs, a biotech company, develops several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune and allergic diseases.

Paris,Ile-de-France,France
11 - 50

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: €6M
Industries: Biotechnology,Health Care,Medical Device,Therapeutics
Founded date: Jan 1, 1993
Number Of Employee: 11 - 50
Operating Status: Active
Stock Symbol: epa:ALNEV

Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are
widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

8

€36.50M

Neovacs has raised a total of €36.50M in funding over 2 rounds. Their latest funding was raised on Jun 22, 2021 from a Post-IPO Debt round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jun 22, 2021	Post-IPO Debt	€4M	—	—	—	Detail
Feb 8, 2021	Post-IPO Debt	€1M	1	—	—	Detail
Jul 31, 2017	Post-IPO Equity	€6M	—	—	—	Detail
Jan 6, 2016	Post-IPO Equity	€5M	1	Bpifrance	—	Detail
Jun 29, 2015	Post-IPO Equity	€7.50M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

2

Neovacs has made 2 investments. Their most recent investment was on Oct 20, 2021, when Signia Therapeutics raised €1.30M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Oct 20, 2021 Signia Therapeutics	Series A	€1.30M	Medical	Yes
Sep 27, 2021 Bio-Detection K9	Series Unknown	$5M	Biotechnology	Yes

Investors

Number of Lead Investors

Number of Investors

3

5

Neovacs is funded by 5 investors. Bpifrance and Novartis Venture Fund are the most recent investors.

Investor Name	Lead Investor	Funding Round
Bpifrance	Yes	Post-IPO Equity
Novartis Venture Fund	Yes	Series Unknown
Debiopharm Innovation Fund	Yes	Series Unknown
Alpha Blue Ocean	—	Post-IPO Debt
Truffle Capital	—	Series Unknown